Cantor Fitzgerald raises Abbvie stock price target to $250 on strong Skyrizi performance

Cantor Fitzgerald has raised its price target for Abbvie's stock to $250, citing strong performance from the drug Skyrizi. This is significant as it reflects confidence in Abbvie's growth potential and the effectiveness of Skyrizi in treating conditions like psoriasis. Investors may see this as a positive indicator for Abbvie's future, potentially leading to increased interest in the stock.